Nasdaq

Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening

Colorectal cancer is the second-leading cause of cancer-related death in the U.S., even though it is highly treatable if caught early.2 The American Cancer Society estimates that more than 150,000 ...
Nasdaq

Guardant Health Receives ADLT Status From CMS for Shield Blood Test

Approval demonstrates unique value of Shield test for CRC screening and improves Medicare pricing The CMS determination confirms that the Shield test meets the criteria for ADLT status, which is ...
Yahoo Finance

American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Business Wire

Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

Strategic collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network Physicians nationwide now have the ability to ...
Business Wire

American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American ...